"Plasma ctDNA monitoring during epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor treatment in patients with EGFR-mutant non-small cell lung cancer (JP-CLEAR trial)"

LAUSR.org creates dashboard-style pages of related content for over 1.5 million academic articles. Sign Up to like articles & get recommendations!

Plasma ctDNA monitoring during epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor treatment in patients with EGFR-mutant non-small cell lung cancer (JP-CLEAR trial)

ctDNA monitoring during EGFR-TKI treatment is useful for detecting T790M mutation. However, the efficacy of osimertinib treatment based on T790M status in plasma ctDNA remains to be established. Click to show full abstract

ctDNA monitoring during EGFR-TKI treatment is useful for detecting T790M mutation. However, the efficacy of osimertinib treatment based on T790M status in plasma ctDNA remains to be established.

Keywords: ctdna; plasma ctdna; ctdna monitoring; treatment; monitoring epidermal

Journal Title: Japanese Journal of Clinical Oncology
Year Published: 2019

Link to full text (if available)

Share on Social Media: Sign Up to like & get
recommendations!
1

LAUSR

You are not signed in:

Sign Up!

Related content

More Information News Social Media Video Recommended